Table 1 Characteristics of 11 studies included in the meta-analysis
Study | Year | Country | design | Men/Patients | Age | Cut-off | Outcome |
|---|---|---|---|---|---|---|---|
Cho [15] | 2018 | Korea | CCS | 214/340 | 68 ± 13 | 14.8 | 28d mortality |
Han [16] | 2018 | China | RCS | 2220/4264 | 68 (54,79) | NM | all-cause mortality |
Kim [17] | 2015 | Korea | CCS | 242/458 | 78.0 (73.8,83.0) | 15.0 | 30d mortality |
Lorente [18] | 2014 | Spain | PCS | 201/297 | 59.5 ± 16.5 | 14.5 | 30d mortality |
Ozdogan [19] | 2015 | Turkey | CCS | 55/103 | 64 ± 14 | 16.0 | hospital mortality |
Wang [12] | 2018 | China | RCS | 70/117 | 81.5 ± 8.3 | 14.5 | hospital mortality |
Ding [20] | 2018 | China | CCS | 50/78 | 65.7 ± 11.5 | 14.0 | 28d mortality |
Gong [21] | 2017 | China | RCS | 121/196 | 60.88 ± 18.11 | 15.0 | 28d mortality |
Li [22] | 2019 | USA | CCS | 6626/11691 | 67.1 ± 17.1 | NM | 28d mortality |
Shen [11] | 2016 | China | CCS | 103/204 | 81.5 ± 7.2 | 14.18 | 30d mortality |
Wang [23] | 2015 | China | PCS | 131/213 | 71.2 ± 16.8 | 15.0 | 28d mortality |